--- title: "Codexi | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.25 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285614377.md" datetime: "2026-05-07T20:36:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285614377.md) - [en](https://longbridge.com/en/news/285614377.md) - [zh-HK](https://longbridge.com/zh-HK/news/285614377.md) --- # Codexi | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 15.25 M Revenue: As of FY2026 Q1, the actual value is USD 15.25 M, beating the estimate of USD 14.53 M. EPS: As of FY2026 Q1, the actual value is USD -0.1, beating the estimate of USD -0.1367. EBIT: As of FY2026 Q1, the actual value is USD -7.418 M. Codexis, Inc. announced its financial results for the quarter ended March 31, 2026, on May 7, 2026, which were furnished as Exhibit 99.1 to a Current Report on Form 8-K . #### Revenue Total revenues for the first quarter of 2026 were $15.2 million, an increase from $7.5 million in the first quarter of 2025, primarily due to an additional $6.3 million in revenue from the Merck Technology Transfer agreement . Product revenue was $7,191 thousand for Q1 2026, compared to $6,059 thousand for Q1 2025 . Research and development revenue increased to $8,057 thousand for Q1 2026, from $1,484 thousand for Q1 2025 . #### Gross Margin Product gross margin for the first quarter of 2026 was 71%, up from 55% in the first quarter of 2025, largely due to a shift towards more profitable products and declines in less profitable legacy products . #### Operating Costs Research and Development expenses decreased to $11.4 million for Q1 2026, from $12.9 million in Q1 2025, mainly due to lower allocable costs . Selling, General & Administrative expenses were $9.8 million for Q1 2026, a decrease from $12.4 million in Q1 2025, primarily due to reduced headcount, lower stock-based compensation, and decreased consultant fees . Total costs and operating expenses were $23,291 thousand for Q1 2026, compared to $28,029 thousand for Q1 2025 . #### Operating Loss Loss from operations improved to -$8,043 thousand for Q1 2026, from -$20,486 thousand for Q1 2025 . #### Net Loss Net loss for the first quarter of 2026 was -$8.7 million, or -$0.10 per share, an improvement from a net loss of -$20.7 million, or -$0.25 per share, for the first quarter of 2025 . In thousands, net loss was -$8,704 thousand for Q1 2026, compared to -$20,688 thousand for Q1 2025 . #### Cash and Investments As of March 31, 2026, Codexis, Inc. held $65.1 million in cash, cash equivalents, and short-term investments . Cash and cash equivalents were $36,571 thousand as of March 31, 2026, down from $50,793 thousand as of December 31, 2025 . Short-term investments increased to $28,569 thousand as of March 31, 2026, from $27,416 thousand as of December 31, 2025 . #### Operational Metrics Codexis, Inc. received ISO 9001 certification for its in-house manufacturing suite and successfully completed a pharmaceutical partner audit . The company supported the production of a pharma biocatalysis product that received FDA approval, bringing the total portfolio to 13 licensed branded pharmaceutical products supported . An agreement was reached to supply 50g of siRNA using the ECO Synthesis manufacturing platform for pre-IND studies . Successful development milestones were achieved for the ECO Synthesis manufacturing platform, enabling superior quality siRNA . #### Outlook / Guidance Codexis, Inc. reiterated its full-year 2026 financial guidance, expecting total revenues to be in the range of $72 million to $76 million . The company anticipates that its existing cash, cash equivalents, and short-term investments will be sufficient to fund planned operations through the end of 2027 . Key upcoming milestones include applying for a building permit for its ECO GMP Manufacturing Center in Q2 2026, commencing retrofit construction in the second half of 2026, and seeking to sign a licensing deal with a major pharmaceutical company in the second half of 2026 . ### Related Stocks - [CDXS.US](https://longbridge.com/en/quote/CDXS.US.md) ## Related News & Research - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [PRO REIT declares May 2026 cash distribution of $0.0375 per unit](https://longbridge.com/en/news/287207393.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [LOWE'S REPORTS FIRST QUARTER 2026 SALES AND EARNINGS RESULTS | LOW Stock News](https://longbridge.com/en/news/287043063.md)